| Bioactivity | Neriifolin, a CNS-penetrating cardiac glycoside, is an inhibitor of the Na+, K+-ATPase. Neriifolin can target beclin 1, inhibits the formation of LC3-associated phagosomes and ameliorates experimental autoimmune encephalomyelitis (EAE) development. Neriifolin induces cell cycle arrest and apoptosis in human hepatocellular carcinoma HepG2 cells[1][2. | |||||||||
| Invitro | Neriifolin (0.1μg/mL; 48 hours) induces apoptosis in HepG2 cells. Neriifolin (0-8 μg/mL; 72 hours) reduces viability of HepG2 cells. Neriifolin also induces S and G2/M phase arrests of the cell cycle and stimulates apoptosis of HepG2 cells. Stimulation of HepG2 cells with Neriifolin induced activation of caspase-3, -8, and -9, and up-regulated expression of Fas and FasL proteins[1]. | |||||||||
| Name | Neriifolin | |||||||||
| CAS | 466-07-9 | |||||||||
| Formula | C30H46O8 | |||||||||
| Molar Mass | 534.68 | |||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | |||||||||
| Storage |
|